(Circulation. 1999;99:2480-2484.)
© 1999 American Heart Association, Inc.
AHA/ACC Scientific Statement: Consensus Panel Statement |
Key Words: AHA Scientific Statements prevention women coronary disease
Coronary heart disease (CHD) is the single leading
cause of death and a significant cause of morbidity among American
women.1 Risk factors for CHD in women are well
documented.2 Compelling data from epidemiological studies
and randomized clinical trials show that CHD is largely preventable.
Assessment and management of several risk factors for CHD are
cost-effective.3 Despite these facts, there are alarming
trends in the prevalence and management of risk factors in
women.2 Smoking rates are declining less for women than
for men. The prevalence of obesity is increasing, and
25% of women
report no regular sustained physical activity.4
Approximately 52% of women >45 years old have elevated blood
pressure, and
40% of women >55 years old have elevated serum
cholesterol.5 The purpose of this statement is
to highlight risk factor management strategies that are appropriate for
women with a broad range of CHD risk. A more detailed description,
including the scientific basis for these recommendations, is available
in the 1997 American Heart Association scientific statement
"Cardiovascular Disease in
Women."2
Recently, the Centers for Disease Control and Prevention National Ambulatory Medical Care Survey6 showed clinicians are missing opportunities to prevent CHD. In this study of 29 273 routine office visits, women were counseled less often than men about exercise, nutrition, and weight reduction. In the multicenter Heart and Estrogen/progestin Replacement Study (HERS),7 only 10% of women enrolled with documented CHD had baseline LDL-cholesterol levels below a National Cholesterol Education Program (NCEP) target of 100 mg/dL. A recent national survey showed that women were significantly less likely than men to enroll in cardiac rehabilitation after an acute myocardial infarction (MI) or bypass surgery.8 This finding is especially important because post-MI patients not enrolled in cardiac rehabilitation are less likely to receive aggressive risk factor management.
Recommendations for the primary and secondary prevention of CHD have been published.9 10 Although those recommendations apply to women, there are aspects of risk factor management that are unique to women. Pregnancy and the preconception period are optimal times to review a woman's risk factor status and health behaviors to reduce future cardiovascular disease. Pregnant women should be strongly encouraged to discontinue smoking and not to relapse in the postpartum period. Avoidance of excess weight gain during pregnancy may reduce the risk of developing CHD in the future. An emphasis on prevention of CHD in postmenopausal women is particularly important because the incidence of CHD rises with age. The use of estrogen replacement therapy (ERT) to prevent CHD, osteoporosis, and possibly dementia is a difficult health decision for postmenopausal women. The potential benefits of therapy must be weighed against the possible risks, including breast cancer, gallbladder disease, thromboembolic disease, and endometrial cancer, although the last is reduced by concomitant use of a progestin.
The recent findings from HERS11 have challenged previous observational data regarding the role of hormones in preventing subsequent cardiovascular events. HERS was the first large-scale, randomized, clinical trial in older postmenopausal women with confirmed coronary disease to test the efficacy and safety of hormone replacement therapy on clinical cardiovascular outcome in postmenopausal women. The study population included 2763 women (mean age 66.7 years) with established CHD randomly assigned to 0.625 mg conjugated equine estrogens (CEE) plus 2.5 mg of medroxyprogesterone acetate (MPA) per day or placebo. Participants were monitored for an average of 4.1 years for the main end point of nonfatal MI or CHD death. At study completion, no significant differences existed between groups for any cardiovascular end points.
Surprisingly, after 1 year, HERS showed an increase in
cardiovascular events in the treatment arm, but in
years 4 and 5, fewer events occurred than in the placebo arm. It has
been hypothesized that possible early adverse effects of estrogen in
women with CHD may be due to a procoagulant effect that may later be
offset by an antiatherogenic benefit. MPA may also have adverse
cardiovascular effects and may mitigate some of the
beneficial effects of estrogen.2 Although these hypotheses
deserve further investigation, the overall null result from HERS does
not support initiation of CEE combined with MPA in older postmenopausal
women with confirmed coronary disease. For women with CHD
already on ERT for
1 year, it may be reasonable to continue therapy
while awaiting the results of a HERS follow-up study and other ongoing
trials of ERT with clinical end points. The results of the HERS trial
apply to women with preexisting CHD and may not apply to women free of
vascular disease. Furthermore, this study does not take into
consideration the other potential benefits of this therapeutic
protocol, which are beyond the scope of this statement.
Data are lacking for determining the long-term cardiovascular effects of testosterone administered with ERT. Alternatives to traditional hormone replacement therapy are available, including soy phytoestrogens and selective estrogen receptor modulators (SERMs); however, a recommendation regarding their use for prevention of CHD has not been made at this time because of a lack of sufficient data.
Several other aspects of risk factor management are of heightened
importance for women. Diabetes is a powerful risk factor in women,
increasing CHD risk 3-fold to 7-fold compared with a 2-fold to 3-fold
increase in risk in men.12 This difference may be due to a
particularly deleterious effect of diabetes on lipids and blood
pressure in women.2 12 Therefore, recommendations are
provided for management of diabetes with an emphasis on controlling
concomitant risk factors.13 Low levels of HDL
cholesterol are predictive of CHD in women and appear to be
a stronger risk factor for women >65 years old than for men
>65.14 Women tend to have higher
HDL-cholesterol levels than men, and
triglyceride levels may be a significant risk factor in
women, especially older women. The current NCEP guidelines are outlined
in the Table![]()
![]()
with a notation to
consider more aggressive targets for HDL cholesterol and
triglycerides in women.15 The NCEP also
recommends the use of ERT before cholesterol-lowering drugs
to reduce LDL cholesterol in postmenopausal women. In this
statement, the recommendation has been modified to consider statins a
first-line therapy in postmenopausal women on the basis of recent data
that suggest women may have at least as much benefit from
LDL-cholesterol reduction with statins as
men.16
|
|
|
Recommendations for aggressive risk factor management are based on the future probability of a cardiovascular event. This strategy allows high-risk patients who have not yet had an event to be considered for more intensive treatment.17 It also recognizes that CHD is not a categorical event but rather a continuum of a progressive disease process. As the availability and use of noninvasive tools to detect asymptomatic CHD increase, the line between primary and secondary prevention may become less distinct. Substantial data support aggressive risk factor management in the setting of secondary prevention. However, because first cardiovascular events are often fatal in women, careful consideration should be given to individual risk factor management before onset of clinical CHD in women. The current recommendations are developed from previous guidelines and consensus panel statements along with newer gender-specific data when available.2 9 10 13 15 18 19 20 21 22 23 The recommendations can serve as a guide to risk factor management but cannot replace clinical judgment. As new knowledge is acquired, revised strategies for the prevention of CHD in women should reflect new science.
Acknowledgments
In addition to the American College of Cardiology and the American Heart Association, the following organizations assisted in the development and review of this document: American Medical Women's Association, American College of Nurse Practitioners, and American College of Obstetricians and Gynecologists.
Footnotes
"A Guide to Preventive Cardiology for Women" was approved by the American College of Cardiology Board of Trustees on February 22, 1999, and by the American Heart Association Science Advisory and Coordinating Committee on September 7, 1998.
A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Avenue, Dallas, TX 75231-4596. Ask for reprint No. 71-0160. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or
References
This article has been cited by other articles:
![]() |
S. J. Nicholls, K. Wolski, I. Sipahi, P. Schoenhagen, T. Crowe, S. R. Kapadia, S. L. Hazen, E. M. Tuzcu, and S. E. Nissen Rate of Progression of Coronary Atherosclerotic Plaque in Women J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1546 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mosca, C. L. Banka, E. J. Benjamin, K. Berra, C. Bushnell, R. J. Dolor, T. G. Ganiats, A. S. Gomes, H. L. Gornik, C. Gracia, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update Circulation, March 20, 2007; 115(11): 1481 - 1501. [Full Text] [PDF] |
||||
![]() |
D. Wang, S. Oparil, Y.-F. Chen, M. A. McCrory, G. A. Skibinski, W. Feng, and A. J. Szalai Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2094 - 2099. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Mieres, L. J. Shaw, A. Arai, M. J. Budoff, S. D. Flamm, W. G. Hundley, T. H. Marwick, L. Mosca, A. R. Patel, M. A. Quinones, et al. Role of Noninvasive Testing in the Clinical Evaluation of Women With Suspected Coronary Artery Disease: Consensus Statement From the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association Circulation, February 8, 2005; 111(5): 682 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mosca, N. B. Merz, R. S. Blumenthal, M. J. Cziraky, R. P. Fabunmi, C. Sarawate, K. E. Watson, V. J. Willey, and E. J. Stanek Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting Circulation, February 1, 2005; 111(4): 488 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Biagini, A. Elhendy, J. J. Bax, V. Rizzello, A. F.L. Schinkel, R. T. van Domburg, M. D. Kertai, B. J. Krenning, M. Bountioukos, C. Rapezzi, et al. Seven-year follow-up after dobutamine stress echocardiography: Impact of gender on prognosis J. Am. Coll. Cardiol., January 4, 2005; 45(1): 93 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gross, M. Steffes, D. R. Jacobs Jr, X. Yu, L. Lewis, C. E. Lewis, and C. M. Loria Plasma F2-Isoprostanes and Coronary Artery Calcification: The CARDIA Study Clin. Chem., January 1, 2005; 51(1): 125 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF] |
||||
![]() |
Expert Panel/Writing Group, L. Mosca, L. J. Appel, E. J. Benjamin, K. Berra, N. Chandra-Strobos, R. P. Fabunmi, D. Grady, C. K. Haan, S. N. Hayes, et al. Evidence-based guidelines for cardiovascular disease prevention in women J. Am. Coll. Cardiol., March 3, 2004; 43(5): 900 - 921. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mosca and for the Expert Panel/WritingGroup Summary of the American Heart Association's Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 394 - 396. [Full Text] |
||||
![]() |
L. Mosca, L. J. Appel, E. J. Benjamin, K. Berra, N. Chandra-Strobos, R. P. Fabunmi, D. Grady, C. K. Haan, S. N. Hayes, D. R. Judelson, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): e29 - 50. [Full Text] |
||||
![]() |
L. Mosca, L. J. Appel, E. J. Benjamin, K. Berra, N. Chandra-Strobos, R. P. Fabunmi, D. Grady, C. K. Haan, S. N. Hayes, D. R. Judelson, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Circulation, February 10, 2004; 109(5): 672 - 693. [Full Text] [PDF] |
||||
![]() |
L. Mosca, A. Ferris, R. Fabunmi, and R. M. Robertson Tracking Women's Awareness of Heart Disease: An American Heart Association National Study Circulation, February 10, 2004; 109(5): 573 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Neves-e-Castro Menopause in crisis post-Women's Health Initiative? A view based on personal clinical experience Hum. Reprod., December 1, 2003; 18(12): 2512 - 2518. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mora, R. F. Redberg, Y. Cui, M. K. Whiteman, J. A. Flaws, A. R. Sharrett, and R. S. Blumenthal Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women: A 20-Year Follow-up of the Lipid Research Clinics Prevalence Study JAMA, September 24, 2003; 290(12): 1600 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rundle, D. Tang, L. Mooney, S. Grumet, and F. Perera The Interaction between Alcohol Consumption and GSTM1 Genotype on Polycyclic Aromatic Hydrocarbon-DNA Adduct Levels in Breast Tissue Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 911 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Natarajan, Y. Liao, G. Cao, S. R. Lipsitz, and D. L. McGee Sex Differences in Risk for Coronary Heart Disease Mortality Associated With Diabetes and Established Coronary Heart Disease Arch Intern Med, July 28, 2003; 163(14): 1735 - 1740. [Abstract] [Full Text] [PDF] |
||||
![]() |
The Exercise Prescription for Older Women Journal Watch Women's Health, March 5, 2003; 2003(305): 2 - 2. [Full Text] |
||||
![]() |
K. D. Graves and P. M. Miller Behavioral Medicine in the Prevention and Treatment of Cardiovascular Disease Behav Modif, January 1, 2003; 27(1): 3 - 25. [Abstract] [PDF] |
||||
![]() |
T. A. Pearson, S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann, B. A. Franklin, L. B. Goldstein, P. Greenland, S. M. Grundy, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation, July 16, 2002; 106(3): 388 - 391. [Full Text] [PDF] |
||||
![]() |
T-M Asikainen, S Miilunpalo, P Oja, M Rinne, M Pasanen, K Uusi-Rasi, and I Vuori Randomised, controlled walking trials in postmenopausal women: the minimum dose to improve aerobic fitness? Br. J. Sports Med., June 1, 2002; 36(3): 189 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oliver-McNeil and N. T. Artinian Women's Perceptions of Personal Cardiovascular Risk and Their Risk-Reducing Behaviors Am. J. Crit. Care., May 1, 2002; 11(3): 221 - 227. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. FRIEDLANDER The physiology, medical management and oral implications of menopause J Am Dent Assoc, January 1, 2002; 133(1): 73 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tolbert, J. A. Thompson, P. Bouchard, and S. Oparil Estrogen-Induced Vasoprotection Is Independent of Inducible Nitric Oxide Synthase Expression: Evidence From the Mouse Carotid Artery Ligation Model Circulation, November 27, 2001; 104(22): 2740 - 2745. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mosca, P. Collins, D. M. Herrington, M. E. Mendelsohn, R. C. Pasternak, R. M. Robertson, K. Schenck-Gustafsson, S. C. Smith Jr, K. A. Taubert, and N. K. Wenger Hormone Replacement Therapy and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association Circulation, July 24, 2001; 104(4): 499 - 503. [Full Text] [PDF] |
||||
![]() |
J. E. Manson and K. A. Martin Postmenopausal Hormone-Replacement Therapy N. Engl. J. Med., July 5, 2001; 345(1): 34 - 40. [Full Text] [PDF] |
||||
![]() |
D. Grady and S. B. Hulley Postmenopausal hormones and heart disease J. Am. Coll. Cardiol., July 1, 2001; 38(1): 8 - 10. [Full Text] [PDF] |
||||
![]() |
R. M. Robertson Women and Cardiovascular Disease : The Risks of Misperception and the Need for Action Circulation, May 15, 2001; 103(19): 2318 - 2320. [Full Text] [PDF] |
||||
![]() |
V. Bittner Estrogens, lipids and cardiovascular disease: no easy answers J. Am. Coll. Cardiol., February 1, 2001; 37(2): 431 - 433. [Full Text] [PDF] |
||||
![]() |
I. J. Goldberg, L. Mosca, M. R. Piano, and E. A. Fisher Wine and Your Heart : A Science Advisory for Healthcare Professionals From the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association Stroke, February 1, 2001; 32(2): 591 - 594. [Full Text] |
||||
![]() |
I. J. Goldberg, L. Mosca, M. R. Piano, and E. A. Fisher Wine and Your Heart : A Science Advisory for Healthcare Professionals From the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association Circulation, January 23, 2001; 103(3): 472 - 475. [Full Text] [PDF] |
||||
![]() |
G. C. Fonarow, W. J. French, L. S. Parsons, H. Sun, and J. A. Malmgren Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction : Data From the National Registry of Myocardial Infarction 3 Circulation, January 2, 2001; 103(1): 38 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Olson, S. F. Kelsey, V. Bittner, S. E. Reis, N. Reichek, E. M. Handberg, C. N. Bairey Merz, and for the Women's Ischemia Syndrome Evaluation (WISE Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: A report from the NHLBI-sponsored WISE study J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1565 - 1571. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Blakely The Heart and Estrogen/Progestin Replacement Study Revisited: Hormone Replacement Therapy Produced Net Harm, Consistent With the Observational Data Arch Intern Med, October 23, 2000; 160(19): 2897 - 2900. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Abramson, L. Mosca, S. M. Grundy, D. Judelson, K. King, M. Limacher, S. Oparil, R. Pasternak, T. A. Pearson, R. F. Redberg, et al. Hormone Replacement Therapy and Cardiac Prevention Response Circulation, June 13, 2000; 101(23): e223 - 224. [Full Text] [PDF] |
||||
![]() |
E Sbarouni, C Kroupis, Z.S Kyriakides, K Koniavitou, and D.T Kremastinos Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease Eur. Heart J., June 2, 2000; 21(12): 975 - 980. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||